Overall, C/EBPβ decreased intracellular Ang II level by up‐regulating ACE2 and Ang(1–7) levels, indicating that C/EBPβ may be more effective in treating DCM than ARBs. This evidence concerns the gene CEBPB and familial dilated cardiomyopathy.